Purification Process Scientist I/II
The Process Scientist will be responsible for supporting downstream process development activities. The candidate for this position will be an integral member of the Process Development team and interact closely with other scientists within Protein Engineering and Manufacturing. He/she will provide production and development support for all pre-clinical programs.
The successful candidate will be responsible for achieving the following objectives:
- Development and execution of protein purification activities supporting proof of concept studies in animal models
- Design of purification methods supporting pre-toxicology process development
- Generation of high quality technical reports required for technology transfer or regulatory requirements
PhD, MS with 3+ years’ or BS with 5+ years’ industry experience in analytical, biophysical, biochemistry, molecular/cell biology, chemical engineering or related field
Experience with and knowledge of separation sciences, process engineering, purification development, chromatography, bio-separation
Knowledge of glycoproteins, enzymes, biophysical/ biochemical characterization and bio-analytical sciences is desirable
Industry experience with these activities as part of a technical role in the support of pre-clinical stage strongly preferred
Detail-oriented personality and ability to work productively in an interdisciplinary team and fast-paced environment
Ability to work successfully with contract manufacturing and research organizations
Commitment to operational excellence
Synageva BioPharma is a publicly traded biopharmaceutical company with headquarters, research and development facilities in Lexington, MA, and research and production facilities in Athens, GA. Synageva is dedicated to developing novel orphan treatments for rare diseases. Our lead program, sebelipase alfa (formerly SBC-102), an enzyme replacement therapy for LAL Deficiency, is in global clinical trials and has been granted orphan designation by the FDA, the European Medicines Agency, and the Japanese Ministry of Health, Labour and Welfare. LAL Deficiency is a rare, serious and devastating disease that leads to significant morbidity and mortality. Synageva has additional orphan products in various stages of preclinical development. To ensure that these therapeutic candidates reach patients in need, Synageva has recruited a team with a proven track record of manufacturing, discovery, development, and commercial success within rare diseases.
Our mission is to deliver breakthrough medicines globally for patients suffering from rare, devastating diseases. Achieving this will result in a sustainable business that can continue to positively impact the lives of patients and their families, healthcare providers and our employees. Our success depends upon our ability to seek and retain principle-minded individuals who share our integrity, drive, energy and passion.
MassBio is a not-for-profit organization committed to advancing the development of critical new science, technology and medicines that benefit people worldwide.
Founded in 1985, MassBio represents over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, and works to advance policy and promote education, while providing member programs and events, industry information, and services.
- May 22, 2013 Drug Repurposing and Reformulation: At the Crossroads of IP, Clinical and Business Strategies
- May 8, 2013 MassBio Recognizes Marlborough as a Major Massachusetts Life Sciences Hub: City Biz List - 5/6/2013
- May 8, 2013 Marlborough commended as tech hub: MetroWest Daily News - 5/7/2013
- May 6, 2013 MassBio Recognizes Marlborough as a Major Life Sciences Hub in Massachusetts: PR.com - 5/5/2013
- May 6, 2013 Elections may have big impact on tech, biotech: Boston Globe - 5/5/2013